Jatenzo Seasonal Use Considerations: What Changes by Season and What to Monitor

Why Seasonal Factors Matter for an Orally Absorbed Testosterone

Jatenzo is the only FDA-approved oral testosterone for male hypogonadism in the United States, and its pharmacokinetics differ substantially from injectable or transdermal formulations. Understanding those differences helps explain why seasonal changes in a patient's daily life can affect circulating testosterone levels and downstream safety parameters.

Lymphatic Absorption and Its Dependence on Dietary Fat

Unlike methyltestosterone (which is hepatotoxic via first-pass metabolism), oral testosterone undecanoate is absorbed through intestinal lymphatics when taken with fat. The oleic-acid vehicle in Jatenzo's soft-gel capsule enters chylomicrons in the enterocyte, bypasses hepatic first pass, and delivers testosterone via the thoracic duct. This process is highly sensitive to the amount and type of fat consumed with each dose [1].

A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism found that co-administration with a high-fat meal (roughly 50 g fat) produced testosterone Cmax values approximately 2.5-fold higher than fasting conditions [2]. Seasonal shifts in eating patterns (lighter summer meals versus heavier winter diets) therefore translate directly into predictable absorption variability.

The 87% Achievement Rate and What It Assumes

In the registration trial by Swerdloff et al. (N=166 men with hypogonadism, 16-week titration period), 87% of patients reached a serum total testosterone within the normal range (300 to 1,000 ng/dL) at three months [1]. That figure was generated under controlled dietary counseling. Real-world patients eating barbecue one week and salads the next may see wider swings.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "Serum testosterone levels should be measured to assess treatment efficacy; levels should be obtained at a consistent time relative to the dose" [3]. In seasonal practice, that consistency is harder to maintain.

Summer: Heat, Hydration, and High-Activity Considerations

Summer presents the most concentrated cluster of variables that can shift Jatenzo pharmacokinetics and safety parameters simultaneously.

Dietary Pattern Shifts in Warm Months

Many patients eat lower-fat meals during summer months: salads, grilled fish, smoothies. Because Jatenzo absorption is fat-gated, a shift from a 40 g fat breakfast in January to a 12 g fat yogurt-and-fruit breakfast in July may reduce testosterone bioavailability by 30 to 40%, based on the dose-proportional fat effect reported in the Jatenzo prescribing information [4].

Practical instruction: patients should be reminded every spring to check the fat content of their typical breakfast and dinner. A minimum of approximately 15 g fat per meal is the threshold supported by the prescribing information label [4]. Avocado, olive oil, whole eggs, or a handful of nuts are simple additions that preserve absorption without dramatically altering caloric load.

Exercise, Hematocrit, and Heat

Intense summer exercise and heat exposure are associated with plasma volume contraction, which concentrates red blood cell mass and raises hematocrit independent of erythropoietic stimulation [5]. Testosterone itself stimulates erythropoiesis through suppression of hepcidin and direct stimulation of erythroid progenitors [6]. The additive effect of testosterone-driven erythropoiesis plus summer dehydration-related hemoconcentration can push hematocrit above the 54% threshold that triggers a dose reduction or temporary hold per the Jatenzo label [4].

A 2013 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (Fernandez-Balsells et al., N=51 trials) found that testosterone therapy increased hematocrit by a weighted mean of 3.2 percentage points compared with placebo (P<0.001) [7]. Adding 2 to 3 percentage points of seasonal hemoconcentration in a patient already at 50% hematocrit is clinically significant.

Recommendation: order a complete blood count in late spring (April, May in the Northern Hemisphere) to establish a pre-summer baseline. Repeat if the patient reports heavy endurance training or if symptoms of erythrocytosis develop.

Blood Pressure and Warm-Weather Vasodilation

The Jatenzo FDA label carries a boxed warning for blood pressure increases. In the Swerdloff registration trial, mean systolic blood pressure rose by 3.6 mmHg from baseline at the end of the treatment period [1]. Summer brings competing effects: peripheral vasodilation from heat may temporarily lower blood pressure, masking a testosterone-related rise that becomes apparent in autumn when vascular tone returns.

Clinicians should measure blood pressure at both summer and autumn visits rather than relying on a single annual reading.

Winter: Reduced Activity, Richer Diet, and Vitamin D Deficiency

Cold months introduce a different set of variables that can increase Jatenzo bioavailability while simultaneously raising cardiometabolic risk.

Fat-Rich Winter Diets and Over-Absorption Risk

Holiday eating, comfort foods, and reduced daylight-driven appetite changes tend to push dietary fat intake upward in winter. A patient consistently eating 60 to 80 g fat per meal may absorb testosterone at the high end of the dose-response curve and drift above the 1,000 ng/dL ceiling of the normal range.

The Swerdloff trial used a titration scheme anchored to mid-dose serum testosterone drawn 4 to 6 hours after the morning dose. Patients whose winter labs show total T above 1,050 ng/dL should have their dose reviewed even if their summer levels were within range.

Vitamin D, Testosterone, and the Seasonal Interaction

Vitamin D deficiency (serum 25-hydroxyvitamin D <20 ng/mL) is prevalent in winter at latitudes above 35°N, affecting roughly 40% of the U.S. Adult population by some estimates [8]. Several observational studies have reported a positive correlation between vitamin D status and endogenous testosterone levels, though causality remains debated.

A randomized controlled trial by Pilz et al. (n=54, Horm Metab Res 2011) found that supplementation with 3,332 IU/day vitamin D3 for 12 months raised total testosterone by 25.2% versus 1.4% in the placebo arm (P<0.001) [9]. For patients on Jatenzo, strong vitamin D status may enhance the background hormonal environment without directly altering oral absorption, but winter deficiency may blunt the clinical response to testosterone therapy at the tissue level. Correcting deficiency with 2,000 to 4,000 IU/day vitamin D3 is reasonable and consistent with Endocrine Society guidance [10].

Physical Activity Decline and Weight Gain

Reduced winter activity and modest weight gain (average 0.5 to 1.5 kg in observational cohorts over winter months) increase visceral adiposity, which in turn raises aromatase activity and elevates estradiol [11]. Higher estradiol provides negative feedback on the hypothalamic-pituitary axis, reducing endogenous testosterone contribution in patients with residual testicular function and potentially altering the testosterone-to-estradiol ratio on exogenous therapy.

This is one mechanism by which patients may report reduced libido or energy in winter despite stable Jatenzo doses. Checking estradiol (estradiol sensitive assay, LC-MS/MS) alongside total testosterone at the winter visit provides actionable data.

Spring and Autumn: Transition Periods Requiring Active Monitoring

The shoulder seasons are when the largest dietary and activity changes occur in the shortest time, making them the highest-risk periods for testosterone level drift.

Spring Transition

Patients who increase exercise intensity rapidly in spring without adjusting meal fat content may simultaneously reduce absorption (lighter meals) while increasing plasma volume through improved cardiovascular conditioning (diluting red cell mass and lowering hematocrit). The result can look like underdosing: lower testosterone, lower hematocrit, and patient-reported fatigue.

Before increasing the Jatenzo dose in response to a low spring testosterone level, confirm that the patient's meal fat intake has remained stable and that the lab draw occurred 4 to 6 hours after the morning dose on a typical eating day. Re-drawing under standardized conditions resolves the ambiguity before a dose escalation.

Autumn Transition

The reverse pattern applies in autumn. Decreased activity, heavier meals, and reduced sweating lower the confounding variables that masked high testosterone in summer. Patients may present with symptoms consistent with excess androgen, such as acne, irritability, or polycythemia, despite the same dose that was tolerated through summer.

An autumn lab draw (October, November) should be considered a standard interval check in addition to the FDA-label-recommended 3 to 4 month post-titration and 6 to 12 month maintenance schedule [4].

Dose Titration Across Seasons: A Practical Framework

The following framework is intended for clinical use alongside the Jatenzo prescribing information and individualized patient assessment. It is not a replacement for clinical judgment.

Step 1: Anchor the Baseline

Establish the patient's "metabolic season" at initiation. Document meal composition (fat grams per dose), typical activity level, body weight, hematocrit, blood pressure, and morning total testosterone. This anchors subsequent seasonal comparisons.

Step 2: Season-Specific Lab Timing

| Season | Recommended Lab Draw Timing | Key Parameters | |--------|----------------------------|----------------| | Winter (Dec, Feb) | 8 to 10 weeks after any holiday dietary change | Total T, estradiol, hematocrit, blood pressure | | Spring (Mar, May) | Before ramping exercise; confirm meal fat stable | Total T, hematocrit, lipid panel | | Summer (Jun, Aug) | 6 weeks after peak activity season begins | Total T, hematocrit, blood pressure, BMP | | Autumn (Sep, Nov) | 4 to 6 weeks after activity and diet normalize | Total T, estradiol, PSA (if age >40) |

Step 3: Titration Rules Aligned With the Label

Per the FDA-approved labeling [4]:

• Start at 158 mg twice daily.
• At 3 to 4 months, measure serum total T 4 to 6 hours after the morning dose.
• If T <300 ng/dL, increase by one dose level (158 mg increments, max 396 mg twice daily).
• If T >1,050 ng/dL, decrease by one dose level.
• Do not adjust based on a single seasonal outlier draw; confirm with a second draw under standardized meal conditions before changing dose.

Step 4: Flag Seasonal Safety Thresholds

Stop or hold Jatenzo if any of the following occur regardless of season:

• Hematocrit above 54% confirmed on repeat [4]
• Systolic BP above 160 mmHg or new hypertension requiring therapy [4]
• Symptomatic VTE or new DVT on imaging [12]

Cardiovascular Risk and Seasonal Superimposition

Cardiovascular events have a well-established seasonal pattern: myocardial infarction incidence peaks in winter months, with a secondary peak in early spring [13]. Testosterone therapy adds its own cardiovascular signal. The FDA-mandated TRAVERSE trial (N=5,246 men with hypogonadism and elevated cardiovascular risk, mean follow-up 33 months) found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE), but there was a higher incidence of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm [12].

The Endocrine Society's Clinical Practice Guideline notes: "We suggest that clinicians consider potential cardiovascular risks before initiating testosterone therapy in men with pre-existing cardiovascular disease" [3]. When seasonal cardiovascular risk is elevated (winter, post-holiday weight gain, reduced activity), extra attention to blood pressure and symptom review is warranted.

Patients with pre-existing hypertension should have home blood pressure logs reviewed at each seasonal visit. A rise of 5 mmHg or more above their established seasonal baseline warrants antihypertensive review before continuing or escalating Jatenzo.

Drug Interactions With a Seasonal Flavor

Some medications used seasonally alter Jatenzo pharmacokinetics or pharmacodynamics.

Corticosteroids for Allergies (Spring)

Spring allergy season drives short-course oral prednisone prescriptions. Corticosteroids suppress the hypothalamic-pituitary axis and may temporarily lower LH and FSH, affecting the background hormonal environment. In men with partial hypothalamic-pituitary function who use Jatenzo, a 5-day prednisone course is unlikely to require dose adjustment, but a longer course (greater than 3 weeks) may warrant a recheck of total testosterone.

NSAIDs for Sports Injuries (Summer)

NSAIDs used for summer sports injuries can raise blood pressure by 3 to 5 mmHg through prostaglandin inhibition [14]. In patients already experiencing testosterone-driven blood pressure elevation, this additive effect may trigger the labeling threshold. Use acetaminophen preferentially in patients with borderline blood pressure on Jatenzo.

Anticoagulants and Erythrocytosis Management

If hematocrit exceeds 54%, the standard clinical response is phlebotomy or dose reduction. Patients on anticoagulants for AF (a risk identified in TRAVERSE) require careful coordination between prescribers before any dose change that alters hematocrit trajectory.

Patient Education Points for Seasonal Self-Management

Patients should receive written instruction at initiation covering the following seasonal self-checks.

Each time a season changes, the patient should ask:

1. Has my breakfast fat content changed? (Target: approximately 15 g or more per meal)
2. Am I more or less physically active than last season?
3. Have I added or stopped any medications?
4. Am I drinking enough water if exercising in heat?

A simple log of meal composition, exercise days per week, and weekly morning blood pressure provides the prescriber with context that transforms a confusing testosterone lab result into an actionable finding.

Monitoring Schedule Summary

The FDA label requires laboratory assessment at 3 to 4 months after initiation or dose change, then every 6 to 12 months. Seasonal considerations argue for adding an interim check at the spring-to-summer transition and the summer-to-autumn transition for the first two years of therapy.

After two years of stable dosing with documented seasonal lab patterns, a patient's individual seasonal curve is established. At that point, the prescriber can set season-specific target ranges rather than treating every lab value against a single annual norm.

Serum total testosterone drawn 4 to 6 hours after the morning Jatenzo dose on a day when the patient ate a standardized fat-containing breakfast is the only clinically comparable measurement. Draws taken fasting, at peak summer activity, or immediately after a holiday week are not equivalent and should be flagged in the chart accordingly.